<DOC>
	<DOCNO>NCT02808871</DOCNO>
	<brief_summary>The purpose study assess safety tolerability pirfenidone 2403 mg/day treatment RA-associated interstitial lung disease .</brief_summary>
	<brief_title>Phase Study Pirfenidone Patients With RAILD</brief_title>
	<detailed_description>This phase 2 , randomize , double blind , placebo control trial pirfenidone treatment RA associate interstitial lung disease . Approximately 270 subject randomize receive Pirfenidone 2403 mg per day placebo 1:1 ratio . The primary outcome study assess efficacy pirfenidone 2403 mg/day versus placebo patient RA associate interstitial lung disease , define progression free survival 52 week treatment . Patients receive blind study treatment time randomization Week 52 Visit . Eligible patient age 18 85 year must meet 2010 ACR/EULAR criterion RA ( Aletaha , Neogi et al . 2010 ) well RA-associated ILD , determine imaging , available , lung biopsy . Patients require % predicted FVC ≥40 ≤80 % predict DLCO ≥30 ≤80 screening . The dose study treatment titrate 14 day . Patients receive telephone assessment Week 1 visit clinic Weeks 2 , 4 , 13 , 16 , 26 , 39 , 52 . Patients complete compliance diary visit . If patient discontinue study treatment reason end study , continue schedule study procedure Week 52 . If subject unable complete study visit schedule , effort make complete early termination visit . The primary outcome variable study progression free survival , define progression free decline FVC 10 % great 52 week study period .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Diagnosis Interstitial Lung Disease : 1 . Diagnosis RA accord revised 2010 ACR/EULAR criterion 2 . Diagnosis RAILD support HRCT available surgical lung biopsy ( SLB ) . 3 . Clinical symptom consistent ILD ( cough , dyspnea ) 4 . Diagnosis ILD , define first instance patient inform ILD , least 6 month randomization 5 . Age 18 85 year , inclusive , randomization 6 . Presence reticular abnormality affect 10 % lung parenchyma , without traction bronchiectasis honeycombing , HRCT 7 . No feature support alternative diagnosis transbronchial biopsy , bronchoalveolar lavage ( BAL ) , SLB , perform ILD Disease Severity Progression : 8 . % FVC ≥ 40 % ≤ 80 % Screening , confirm central review 9 . Change pre postbronchodilator FVC ( measure liter ) Screening ( Visit 1 ) Visit 2 must &lt; 10 % relative difference , calculate show : Screen FVC ( L ) Day 1 FVC ( L ) × 100 % Screen FVC ( L ) 10 . % DLCO ≥30 % ≤80 % Screening , confirm central review 11 . Stable dose ( least three month ) corticosteroid cytotoxic , immunosuppressive cytokinemodulating , receptor antagonist agent include limited azathioprine , cyclophosphamide , cyclosporine , etanercept , iloprost , infliximab , leukotriene antagonist , methotrexate , mycophenolate mofetil , tacrolimus , montelukast , tetrathiomolybdate , TNFα inhibitor , rituximab , abatacept , tofacitintib , tociluzimab prescribe rheumatoid arthritis . 12 . Presence fibrotic change affect 10 % lung parenchyma , without traction bronchiectasis honeycombing , HRCT Informed Consent Protocol Adherence : 13 . Able understand sign write informed consent form 14 . Able understand importance adherence study treatment study protocol willing follow study requirement , include concomitant medication restriction , throughout study DiseaseRelated Exclusions : 1 . Not suitable candidate enrollment unlikely comply requirement study , opinion investigator 2 . Cigarette smoke within 3 month Screening unwilling avoid tobacco product throughout study 3 . History clinically significant environmental exposure know cause pulmonary fibrosis ( PF ) , include limited drug ( amiodarone ) , asbestos , beryllium , radiation , domestic bird 4 . Concurrent presence interstitial lung disease , include limited radiation , drug toxicity , sarcoidosis , hypersensitivity pneumonitis , bronchiolitis obliterans organize pneumonia , human immunodeficiency virus ( HIV ) , viral hepatitis , cancer 5 . Concurrent presence pleuropulmonary manifestation RA , include limited rheumatoid nodular disease lung , pleuritis/pleural thickening , obliterative bronchiolitis 6 . Postbronchodilator FEV1/FVC &lt; 0.7 7 . Presence pleural effusion occupy 20 % hemithorax 8 . Clinical diagnosis second connective tissue disease overlap syndrome ( include limit scleroderma , polymyositis/dermatomyositis , systemic lupus erythematosus ) 9 . Coexistent clinically significant COPD/emphysema asthma opinion site principle investigator Medical Exclusions : 10 . Clinical evidence active infection , include limited bronchitis , pneumonia , sinusitis , urinary tract infection , cellulitis 11 . Any history malignancy diagnose within 5 year screen , basal cell carcinoma skin , squamous cell carcinoma skin , low grade cervical carcinoma situ . History severe hepatic impairment endstage liver disease 12 . History endstage renal disease require dialysis 13 . History unstable deteriorate cardiac disease , myocardial infarction within previous year , heart failure within last 3 year , cardiac arrhythmia require drug therapy 14 . Any condition , opinion investigator , might significantly exacerbate know side effect associate administration pirfenidone 15 . Pregnancy lactation . Women childbearing capacity require negative serum pregnancy test treatment must agree maintain highly effective contraception practice abstinence use least two method birth control date consent end study . If abstinence practice , one two method birth control oral contraceptive ( e.g. , oral contraceptive spermicide ) . 16 . Investigational therapy , define drug approve marketing indication country participate site 17 . History alcohol substance abuse past 2 year 18 . Family personal history long QT syndrome Laboratory Exclusions : 19 . Any following liver function test criterion specify limit : 1 . Total bilirubin upper limit normal ( ULN ) , exclude patient Gilbert 's syndrome ; aspartate alanine aminotransferase ( AST/SGOT ALT/SGPT ) &gt; 3 × ULN ; alkaline phosphatase &gt; 2.5 × ULN 2 . Creatinine clearance ( CrCl &lt; 30 ) mL/min , calculate use CockcroftGault formula 3 . Electrocardiogram ( ECG ) QTcB interval &gt; 500 msec Screening Medication Exclusions : 20 . Prior use pirfenidone know hypersensitivity component study treatment 21 . Use follow therapy within 28 day Screening : 1 . Investigational therapy , define drug approve marketing indication country participate site 2 . Fluvoxamine 3 . Sildenafil ( daily use ) . Note : intermittent use erectile dysfunction allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>